SERUM NT-PROBNP, ACYLGHRELIN, DESACYLGHRELIN, OBESTATIN, AND FATTY ACID BINDING PROTEIN 4 LEVELS IN HEMODIALYSIS PATIENT

Hulya Taskapan¹, Cagatay Taskapan², Fatma Ozyalin², Ali Dogan³, ¹Inonu University, Nephrology Department, Malatya, TURKEY, ²Inonu University Medical Faculty, Biochemistry, Malatya, TURKEY, ³Yuzuncu Yıl University, Internal Medicine, Van, TURKEY.

INTRODUCTION AND AIMS:Three distinct ghrelin gene products, namely, acylghrelin, desacylghrelin, and obestatin have been identified. Acylghrelin is a potent stimulator of food intake and gastrointestinal motility while desacyl ghrelin exerts opposite effects on food intake and gastrointestinal motility. The effects of obestatin on food intake and gastrointestinal motility have been controversial. Fatty acid-binding protein 4 (FABP4) mainly expressed in adipocytes and macrophages is associated with obesity, insulin resistance, and atherosclerosis. A positive relationship between serum ghrelin and NT-proBNP levels in patients with heart failure or pulmonary hypertension was reported. The present study investigated the relationships among acylghrelin, deacylghrelin levels, obestatin, FABP4 and the N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) in hemodialysis dialysis (HD) patients.

METHODS:The study included 60 hemodialysis (30 male, 30 female) and 20 (9 male, 11 female) age, gender and body mass index (BMI) matched healthy control subjects. Serum ghrelin, obestatin and FABP4 levels were measured by enzyme immunoassay (ELI-SA, Enzyme Linked Immunosorbent Assay). NT-proBNP levels were determined using chemiluminescent immunometric assay.

RESULTS: Serum desacylghrelin, FAB4 and NT-proBNP levels were higher in HD patients [(1080,9±602,8 vs 499,9±313,6 pg/mL), (11,7±2,7 vs 1,9±0,8 ng/mL), (12946,2±15279,6 vs189,3±195,6 pg/mL) respectively] than those of controls (p:0.000). There was no difference according to serum acylghrelin, and obestatin levels between HD patients and controls (Table 1). Serum acylghrelin levels were positively correlated with serum albumin levels (r:0.282, p:0.029), wherease serum acylghrelin levels were negatively correlated with serum desacylghrelin levels (r:-0.358, p:0.005). Serum acylghrelin levels were not correlated with age, dialysis duration, serum creatinine, albumin, calcium, phosphate, obestatin, FAB4, NT-proBNP and intact parathroid hormone (iPTH) levels (p>0.05). Serum deacylghrelin levels were negatively correlated with acylghrelin (r:-0.358, p:0.005) and iPTH levels (r:-0.278, p:0.032). Serum desacylghrelin levels were not correlated with age, dialysis duration, serum creatinine, albumin, calcium, phosphate, obestatin, calcium, phosphate, obestatin, nT-proBNP, and FAB4 levels (p>0.05). Serum MT-proBNP levels were not correlated with age, dialysis duration, serum creatinine, albumin, calcium, phosphate, iPTH, acylghrelin, desacylghrelin, obestatin, and FAB4 levels (p>0.05). Serum FAB4 levels were positively correlated with serum phosphate levels (r:0.387, p:0.002). Serum FAB4 levels were not correlated with age, dialysis duration, serum creatinine, albumin, calcium, phosphate, iPTH, acylghrelin, obestatin, and NT-proBNP levels (p>0.05). Table 2 shows correlation among serum NT-proBNP, acylghrelin, desacylghrelin, obestatin, and fatty acid-binding protein 4 levels in hemodialysis patients,

CONCLUSIONS: In HD patients serum NT-proBNP levels were not correlated with serum acylghrelin, desacylghrelin, obestatin, and FAB4 levels while serum acylghrelin was negatively correlated with serum desacylghrelin levels. Serum desacylghrelin and FAB4 levels were higher in HD patients than those of controls. Some studies reported that serum desacylghrelin level and FAB4 were useful cardiometabolic markers for predicting atherosclerosis in patients with normal kidney function. Further studies are needed to clarify whether high desacylghrelin and FAB4 levels in HD patients contribute to atherosclerosis.

REFERENCES


- 1. Borges N, Moraes C, Barros AF et al. Acyl-ghrelin and obestatin plasma levels in different stages of chronic kidney disease. J Ren Nutr 2014;24(2):100-4.
- 2. Sommer G, Ziegelmeier M, Bachmann A et al. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD). Clin Endocrinol. 2008;69(6):901-5.
- 3. Tsai JP Liou HH, Liu HM et al. Fasting serum fatty acid-binding protein 4 level positively correlates with metabolic syndrome in hemodialysis patients . Arch Med Res 2010;41(7):536-40
- 4. Yang D, Liu Z, Yang Z. Ghrelin and its relation with terminal brain peptide, endothelin 1 and nitric oxide in patients with idiopathic pulmonary hypertension. Cardiology. 2013;124(4):241-5
- 5. Gouya G, Voithofer P, Neuhold S, Storka A, Vila G, Pacher R, Wolzt M, Hülsmann M Association of nutritional risk index with metabolic biomarkers, appetite-regulatory hormons and inflammatory biomarkers and outcome in patients with chronic heart failure Int J Clin Pract. 2014 Nov;68(11):1293-300

6. Chen Y, Ji XW, Zhang AY, Lv JC, Zhang JG, Zhao CH Prognostic value of plasma ghrelin in predicting the outcome of patients with chronic heart failure . Arch Med Res. 2014;45(3):263-9

	HD patients	Controls	
	N: 60	N:20	
Age (years) BMI (kg/m²) NT-proBNP (pg/mL) FAB4 (pg/mL) Obestatin (ng/mL) Acyghrelin (pg/mL) Desacyghrelin (pg/mL)	Mean± Std. Deviation	Mean ±Std. Deviation	р
	57,6±15,9	54,5±11,4	0,234
	25,8±5,5	26,8±4,8	0,374
	12946,2±15279,6	189,3±195,6	0.000
	11,7±2,7	1,9±0,8	0,000 0,463
	5,9±2,3	6,1±1,8	
	14,2±21,4	16,5±25,3	0,920
	1080,9±602,8	499,9±313,6	0.000

Table 2.Correlation among Serum NT-proBNP, acylghrelin, desacylghrelin, obestatin, and Fatty acid-binding protein 4 levels in hemodialysis patients

		NT-proBNP	FAB4	Obestatin	Acyghrelin	Desacyghrelin
NT-proBNP	r	1,000	0,148	-0,068	-0,146	0,214
	р		0,258	0,608	0,267	0,100
FAB4 obestatin	r	0,148	1,000	-0,094	-0,145	0,101
	р	0,258		0,473	0,271	0,441
	r	-0,068	-0,094	1,000	-0,153	0,196
	р	0,608	0,473	•	0,242	0,134
Acyghrelin	р	0,114	0,469	0,137	0,009	0,000
	r	-0,146	-0,145	-0,153	1,000	-0,358**
Desacyghrelin	р	0,267	0,271	0,242	•	0,005
	r	0,214	0,101	0,196	-0,358**	1,000
	р	,100	0,441	0,134	0,005	







DOI: 10.3252/pso.eu.54ERA.2017